AstraZeneca: Positive TEZSPIRE results from the eosinophilic esophagitis phase III CROSSING trial were announced at the European Joint Gastroenterology Week, including symptom improvement, histology, and endoscopic remission.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.